Cell Line Origin
Mouse DBA/2 lymphoid neoplasm derivative; drug resistant
Cell Line Description
The cell line Pr8/22 has been derived from P388, a methylcholanthrene-induced lymphoid neoplasm originating in DBA/2 mouse and converted to ascitic form in the first mouse transfer. Pr8/22 is resistant to daunorubicin and is multi drug resistant (MDR). Cells should be treated with the drug at least once a month and before freezing, however after resuscitating daunorubicin should not be added until the first passage. It is advisable to keep a backup culture which is not drug-challenged.
Application
Study of drug-resistance
Culture Medium
RPMI 1640 + 2mM Glutamine + 10% Horse Serum (HS); treat once a month with 0.1μM Daunorubicin
Subculture Routine
Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37°C. It is recommended to culture the cells without drug upon resuscitation until the first passage
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
Disclaimer
This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.
biological source: mouse lymph. growth mode: Suspension. karyotype: Not specified. morphology: Not specified. products: Not specified. receptors: Not specified. technique(s): cell culture | mammalian: suitable. relevant disease(s): cancer. shipped in: dry ice. storage temp.: −. 196°C.- UPC:
- 51281805
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 93112518-1VL